Screening for Regenerative Therapy Responders in Heart Failure

References

• Sulaica EM , WollenJT, KotterJ, MacaulayTE. A review of hypertension management in black male patients. Mayo Clin. Proc.95(9), 1955–1963 (2020).
   PubMed Web of Science ®Google Scholar
• Vasan N , BaselgaJ, HymanDM. A view on drug resistance in cancer. Nature575(7782), 299–309 (2019).
   PubMed Web of Science ®Google Scholar
• Vicini FA , CecchiniRS, WhiteJRet al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, Phase III, equivalence trial. Lancet394(10215), 2155–2164 (2019).
   PubMed Web of Science ®Google Scholar
• Dennis JM . Precision medicine in Type 2 diabetes: using individualized prediction models to optimize selection of treatment. Diabetes69(10), 2075–2085 (2020).
   PubMed Web of Science ®Google Scholar
• Harvey ES , LangtonD, KatelarisCet al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur. Respir. J.55(5), 1902420 (2020).
   PubMed Web of Science ®Google Scholar
• Bondar J , CayeA, ChekroudAM, KielingC. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the treatment for adolescents with depression study randomised trial. Lancet Psych.7(4), 337–343 (2020).
   PubMed Web of Science ®Google Scholar
• Fogel DB . Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp. Clin. Trials Commun.11, 156–164 (2018).
   PubMed Web of Science ®Google Scholar
• Fazio M , AblainJ, ChuanY, LangenauDM, ZonLI. Zebrafish patient avatars in cancer biology and precision cancer therapy. Nat. Rev. Cancer20(5), 263–273 (2020).
   PubMed Web of Science ®Google Scholar
• Lauffenburger JC , ChoudhryNK. Call for a systems-thinking approach to medication adherence: stop blaming the patient. JAMA Intern. Med.178(7), 950–951 (2018).
   PubMed Web of Science ®Google Scholar
• Kent DM , PaulusJK, van KlaverenDet al. The predictive approaches to treatment effect heterogeneity (PATH) statement: explanation and elaboration. Ann. Intern. Med.172(1), W1–W25 (2020).
   PubMed Web of Science ®Google Scholar
• Leask F , TerzicA. Regenerative outlook: offering global solutions for equity of care. Regen. Med.15(11), 2249–2252 (2020).
   PubMed Web of Science ®Google Scholar
• Terzic A , BehfarA. Regenerative medicine in the practice of cardiology. Eur. Heart J.37(14), 1089–1090 (2016).
   PubMed Web of Science ®Google Scholar
• Banerjee MN , BolliR, HareJM. Clinical studies of cell therapy in cardiovascular medicine: recent developments and future directions. Circ. Res.123(2), 266–287 (2018).
   PubMed Web of Science ®Google Scholar
• Johnston PV , DuckersHJ, RavalAN, CookTD, PepineCJ. Not all stem cells are created equal: the case for prospective assessment of stem cell potency in the CardiAMP heart failure trial. Circ. Res.123(8), 944–946 (2018).
   PubMed Web of Science ®Google Scholar
• Frangos S , BuscombeJR. Why should we be concerned about a “g”?Eur. J. Nucl. Med. Mol. Imaging46, 519 (2019).
   PubMed Web of Science ®Google Scholar
• Braunwald E . Heart failure. JACC Heart Fail.1(1), 1–20 (2013).
   PubMed Web of Science ®Google Scholar
• Shah SJ , BorlaugBA, KitzmanDWet al. Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation141(12), 1001–1026 (2020).
   PubMed Web of Science ®Google Scholar
• Cahill TJ , AshrafianH, WatkinsH. Genetic cardiomyopathies causing heart failure. Circ. Res.113(6), 660–675 (2013).
   PubMed Web of Science ®Google Scholar
• McMurray JJ . Clinical practice. Systolic heart failure. N. Engl. J. Med.362(3), 228–238 (2010).
   PubMed Web of Science ®Google Scholar
• Kirk JA , KassDA. Electromechanical dyssynchrony and resynchronization of the failing heart. Circ. Res.113(6), 765–776 (2013).
   PubMed Web of Science ®Google Scholar
• Normand C , KayeDM, PovsicTJ, DicksteinK. Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. Lancet393(10175), 1045–1055 (2019).
   PubMed Web of Science ®Google Scholar
• Yamada S , TerzicA. Path toward proactive therapy for patent ductus arteriosus. Clin. Pharmacol. Ther.106(6), 1187–1190 (2019).
   PubMed Web of Science ®Google Scholar
• Terzic A , BehfarA. Stem cell therapy for heart failure: ensuring regenerative proficiency. Trends Cardiovasc. Med.26(5), 395–404 (2016).
   PubMed Web of Science ®Google Scholar
• Honig P , TerzicA. Affairs of the heart: innovation in cardiovascular research and development. Clin. Pharmacol. Ther.102(2), 162–168 (2017).
   PubMed Web of Science ®Google Scholar
• Yancy CW , JessupM, BozkurtBet al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation136(6), e137–e161 (2017).
   PubMed Web of Science ®Google Scholar
• Salden OAE , VernooyK, van StipdonkAMW, CramerMJ, PrinzenFW, MeineM. Strategies to improve selection of patients without typical left bundle branch block for cardiac resynchronization therapy. JACC Clin. Electrophysiol.6(2), 129–142 (2020).
   PubMedGoogle Scholar
• Heggermont W , AuricchioA, VanderheydenM. Biomarkers to predict the response to cardiac resynchronization therapy. Europace21(11), 1609–1620 (2019).
   PubMed Web of Science ®Google Scholar
• Yamada S , NelsonTJ, KaneGCet al. Induced pluripotent stem cell intervention rescues ventricular wall motion disparity, achieving biological cardiac resynchronization post-infarction. J. Physiol.591(17), 4335–4349 (2013).
   PubMed Web of Science ®Google Scholar
• Terzic A , BehfarA. Regenerative heart failure therapy headed for optimization. Eur. Heart J.35(19), 1231–1234 (2014).
   PubMed Web of Science ®Google Scholar
• Braunwald E . The war against heart failure: the Lancet lecture. Lancet385(9970), 812–824 (2015).
   PubMed Web of Science ®Google Scholar
• Yamada S , BehfarA, TerzicA. Regenerative medicine clinical readiness. Regen. Med.16(3), 309–322 (2021).
   PubMedGoogle Scholar
• Ho D . Artificial intelligence in cancer therapy. Science367(6481), 982–983 (2020).
   PubMed Web of Science ®Google Scholar
• Terzic A , BehfarA, FilippatosG. Clinical development plan for regenerative therapy in heart failure. Eur. J. Heart Fail.18(2), 142–144 (2016).
   PubMed Web of Science ®Google Scholar
• Raval AN , CookTD, DuckersHJet al. The CardiAMP Heart Failure trial: a randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: trial rationale and study design. Am. Heart J.201, 141–148 (2018).
   PubMed Web of Science ®Google Scholar
• Bartunek J , TerzicA, BehfarA, WijnsW. Clinical experience with regenerative therapy in heart failure: advancing care with cardiopoietic stem cell interventions. Circ. Res.122(10), 1344–1346 (2018).
   PubMed Web of Science ®Google Scholar
• Raval AN , JohnstonPV, DuckersHJet al. Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. Int. J. Cardiol.326, 131–138 (2021).
   PubMed Web of Science ®Google Scholar
• Bartunek J , BehfarA, DolatabadiDet al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J. Am. Coll. Cardiol.61(23), 2329–2338 (2013).
   PubMed Web of Science ®Google Scholar
• Bartunek J , TerzicA, CHARTProgramet al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur. Heart J.38(9), 648–660 (2017).
   PubMed Web of Science ®Google Scholar
• Teerlink JR , MetraM, CHARTInvestigatorset al. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the congestive heart failure cardiopoietic regenerative therapy (CHART-1) study. Eur. J. Heart Fail.19(11), 1520–1529 (2017).
   PubMed Web of Science ®Google Scholar
• Behfar A , YamadaS, Crespo-DiazRet al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J. Am. Coll. Cardiol.56(9), 721–734 (2010).
   PubMed Web of Science ®Google Scholar
• Behfar A , TerzicA. Stem cell in the rough: repair quotient mined out of a bone marrow niche. Circ. Res.115(10), 814–816 (2014).
   PubMed Web of Science ®Google Scholar
• Borow KM , YaroshinskyA, GreenbergB, PerinEC. Phase III DREAM-HF trial of mesenchymal precursor cells in chronic heart failure. Circ. Res.125(3), 265–281 (2019).
   PubMed Web of Science ®Google Scholar
• Rieger AC , MyerburgRJ, FloreaVet al. Genetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy. EBioMedicine48, 377–385 (2019).
   PubMed Web of Science ®Google Scholar
• Boumahdi S , de SauvageFJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov.19(1), 39–56 (2020).
   PubMed Web of Science ®Google Scholar
• Jokerst JV , CauwenberghsN, KuznetsovaTet al. Circulating biomarkers to identify responders in cardiac cell therapy. Sci. Rep.7(1), 4419 (2017).
   PubMedGoogle Scholar
• Bartunek J , TerzicA, DavisonBAet al. Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. ESC Heart Failure7(6), 3345–3354 (2020).
   PubMed Web of Science ®Google Scholar
• Frljak S , PoglajenG, ZemljicGet al. Larger end-diastolic volume associates with response to cell therapy in patients with non-ischemic dilated cardiomyopathy. Mayo Clin. Proc.95(10), 2125–2133 (2020).
   PubMed Web of Science ®Google Scholar
• Yamada S , ArrellDK, RosenowCS, BartunekJ, BehfarA, TerzicA. Ventricular remodeling in ischemic heart failure stratifies responders to stem cell therapy. Stem Cells Transl. Med.9(1), 74–79 (2020).
   PubMed Web of Science ®Google Scholar
• Bax JJ , DiCarli M, NarulaJ, DelgadoV. Multimodality imaging in ischaemic heart failure. Lancet393(10175), 1056–1070 (2019).
   PubMed Web of Science ®Google Scholar
• Yamada S , ArrellDK, KaneGCet al. Mechanical dyssynchrony precedes QRS widening in ATP-sensitive K+ channel-deficient dilated cardiomyopathy. J. Am. Heart Assoc.2(6), e000410 (2013).
   PubMed Web of Science ®Google Scholar
• Yamada S , ArrellDK, Martinez-FernandezAet al. Regenerative therapy prevents heart failure progression in dyssynchronous nonischemic narrow QRS cardiomyopathy. J. Am. Heart Assoc.4(5), e001614 (2015).
   PubMed Web of Science ®Google Scholar
• Arrell DK , RosenowCS, YamadaS, BehfarA, TerzicA. Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome. NPJ Regen. Med.5, 5 (2020).
   PubMed Web of Science ®Google Scholar
• Densen P . Challenges and opportunities facing medical education. Trans. Am. Clin. Climatol. Assoc.122, 48–58 (2011).
   PubMedGoogle Scholar
• Chow SL , MaiselAS, AnandIet al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation135(22), e1054–e1091 (2017).
   PubMed Web of Science ®Google Scholar
• Barth AS , KumordzieA, FrangakisCet al. Reciprocal transcriptional regulation of metabolic and signaling pathways correlates with disease severity in heart failure. Circ. Cardiovasc. Genet.4(5), 475–483 (2011).
   PubMedGoogle Scholar
• Rajkomar A , DeanJ, KohaneI. Machine learning in medicine. N. Engl. J. Med.380(14), 1347–1358 (2019).
   PubMed Web of Science ®Google Scholar
• Attia ZI , KapaS, Lopez-JimenezFet al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat. Med.25(1), 70–74 (2019).
   PubMed Web of Science ®Google Scholar
• Attia ZI , NoseworthyPA, Lopez-JimenezFet al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet394(10201), 861–867 (2019).
   PubMed Web of Science ®Google Scholar
• Kather JN , CalderaroJ. Development of AI-based pathology biomarkers in gastrointestinal and liver cancer. Nat. Rev. Gastroenterol. Hepatol.17(10), 591–592 (2020).
   PubMed Web of Science ®Google Scholar
• Dey D , SlomkaPJ, LeesonPet al. Artificial intelligence in cardiovascular imaging: JACC state-of-the-art review. J. Am. Coll. Cardiol.73(11), 1317–1335 (2019).
   PubMed Web of Science ®Google Scholar
• Wouters OJ , McKeeM, LuytenJ. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA323(9), 844–853 (2020).
   PubMed Web of Science ®Google Scholar
• Schaub NJ , HotalingNA, ManescuPet al. Deep learning predicts function of live retinal pigment epithelium from quantitative microscopy. J. Clin. Invest.130(2), 1010–1023 (2020).
   PubMed Web of Science ®Google Scholar
• Lee Y , RagguettRM, MansurRBet al. Applications of machine learning algorithms to predict therapeutic outcomes in depression: a meta-analysis and systematic review. J. Affect. Disord.241, 519–532 (2018).
   PubMed Web of Science ®Google Scholar
• Hilton CB , MilinovichA, FelixCet al. Personalized predictions of patient outcomes during and after hospitalization using artificial intelligence. NPJ Digit. Med.3(3), 51 (2020).
   PubMedGoogle Scholar
• Li Y , SperrinM, AshcroftDM, van StaaTP. Consistency of variety of machine learning and statistical models in predicting clinical risks of individual patients: longitudinal cohort study using cardiovascular disease as exemplar. BMJ371, m3919 (2020).
   PubMedGoogle Scholar
• Fernández-Avilés F , Sanz-RuizR, TheTACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) writing groupet al. Global position paper on cardiovascular regenerative medicine. Eur. Heart J.38(33), 2532–2546 (2017).
   PubMed Web of Science ®Google Scholar
• Marbán E . A mechanistic roadmap for the clinical application of cardiac cell therapies. Nat. Biomed. Eng.2(6), 353–361 (2018).
   PubMed Web of Science ®Google Scholar
• Blau HM , DaleyGQ. Stem cells in the treatment of disease. N. Engl. J. Med.380(18), 1748–1760 (2019).
   PubMed Web of Science ®Google Scholar
• Menasche P . Cardiac cell therapy: current status, challenges and perspectives. Arch. Cardiovasc. Dis.113(4), 285–292 (2020).
   PubMed Web of Science ®Google Scholar
• Cossu G , FearsR, GriffinG, MeulenV. Regenerative medicine: challenges and opportunities. Lancet395(10239), 1746–1747 (2020).
   PubMed Web of Science ®Google Scholar